Treatment of Wilms tumor relapsing after initial treatment with vincristine and actinomycin D

A report from the National Wilms Tumor Study Group

Daniel M. Green, Cecilia A. Cotton, Marcio Malogolowkin, Norman E. Breslow, Elizabeth Perlman, James Miser, Michael L. Ritchey, Patrick R M Thomas, Paul E. Grundy, Giulio J. D'Angio, J. Bruce Beckwith, Robert C. Shamberger, Gerald M. Haase, Milton Donaldson, Robert Weetman, Max J. Coppes, Patricia Shearer, Peter Coccia, Morris Kletzel, Roger Macklis & 4 others Gail Tomlinson, Vicki Huff, Robert Newbury, Douglas Weeks

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Purpose. NWTS-5 was a multi-institutional clinical trial for patients less than 16 years of age at diagnosis with specific renal neoplasms who were diagnosed between August 1, 1995 and May 31, 2002. A uniform approach to the treatment of patients with relapse was employed. Patients and Methods. Seventy-two patients who relapsed after immediate nephrectomy (stages I and II), initial chemotherapy with vincristine (VCR) and actinomycin D and no radiation therapy were registered on stratum B of the NWTS-5 relapse protocol. Four patients were not evaluable: one due to insufficient data and three due to major protocol violations. Among the 68 remaining patients, one who was 19 years of age at initial diagnosis of Wilms tumor, five with bilateral Wilms tumor at diagnosis, three who developed a contralateral relapse, and one with persistent disease were not included in this analysis. Relapse treatment included surgical excision, when feasible, radiation therapy and alternating courses of VCR, doxorubicin and cyclophosphamide and etoposide and cyclophosphamide. Results. The outcomes of 58 patients were analyzed. The lung was the only site of relapse for 31 patients. Event-free survival 4 years after relapse was 71.1% and 4-year overall survival was 81.8% for all patients and were 67.8 and 81.0% for those who relapsed only to their lungs. The most frequent toxicities were hematological. Conclusions. These results demonstrate that a significant proportion of children with Wilms tumor who relapse after initial treatment with VCR and actinomycin D can be successfully re-treated.

Original languageEnglish (US)
Pages (from-to)493-499
Number of pages7
JournalPediatric Blood and Cancer
Volume48
Issue number5
DOIs
StatePublished - May 1 2007
Externally publishedYes

Fingerprint

Wilms Tumor
Dactinomycin
Vincristine
Recurrence
Therapeutics
Cyclophosphamide
Radiotherapy
Lung
Kidney Neoplasms
Etoposide
Nephrectomy
Doxorubicin
Disease-Free Survival
Clinical Trials
Drug Therapy
Survival

Keywords

  • Chemotherapy
  • Pediatric oncology
  • Phase II clinical trials
  • Wilms tumor

ASJC Scopus subject areas

  • Cancer Research
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Treatment of Wilms tumor relapsing after initial treatment with vincristine and actinomycin D : A report from the National Wilms Tumor Study Group. / Green, Daniel M.; Cotton, Cecilia A.; Malogolowkin, Marcio; Breslow, Norman E.; Perlman, Elizabeth; Miser, James; Ritchey, Michael L.; Thomas, Patrick R M; Grundy, Paul E.; D'Angio, Giulio J.; Beckwith, J. Bruce; Shamberger, Robert C.; Haase, Gerald M.; Donaldson, Milton; Weetman, Robert; Coppes, Max J.; Shearer, Patricia; Coccia, Peter; Kletzel, Morris; Macklis, Roger; Tomlinson, Gail; Huff, Vicki; Newbury, Robert; Weeks, Douglas.

In: Pediatric Blood and Cancer, Vol. 48, No. 5, 01.05.2007, p. 493-499.

Research output: Contribution to journalArticle

Green, DM, Cotton, CA, Malogolowkin, M, Breslow, NE, Perlman, E, Miser, J, Ritchey, ML, Thomas, PRM, Grundy, PE, D'Angio, GJ, Beckwith, JB, Shamberger, RC, Haase, GM, Donaldson, M, Weetman, R, Coppes, MJ, Shearer, P, Coccia, P, Kletzel, M, Macklis, R, Tomlinson, G, Huff, V, Newbury, R & Weeks, D 2007, 'Treatment of Wilms tumor relapsing after initial treatment with vincristine and actinomycin D: A report from the National Wilms Tumor Study Group', Pediatric Blood and Cancer, vol. 48, no. 5, pp. 493-499. https://doi.org/10.1002/pbc.20822
Green, Daniel M. ; Cotton, Cecilia A. ; Malogolowkin, Marcio ; Breslow, Norman E. ; Perlman, Elizabeth ; Miser, James ; Ritchey, Michael L. ; Thomas, Patrick R M ; Grundy, Paul E. ; D'Angio, Giulio J. ; Beckwith, J. Bruce ; Shamberger, Robert C. ; Haase, Gerald M. ; Donaldson, Milton ; Weetman, Robert ; Coppes, Max J. ; Shearer, Patricia ; Coccia, Peter ; Kletzel, Morris ; Macklis, Roger ; Tomlinson, Gail ; Huff, Vicki ; Newbury, Robert ; Weeks, Douglas. / Treatment of Wilms tumor relapsing after initial treatment with vincristine and actinomycin D : A report from the National Wilms Tumor Study Group. In: Pediatric Blood and Cancer. 2007 ; Vol. 48, No. 5. pp. 493-499.
@article{ef508c66416e426cac7894f031294cb0,
title = "Treatment of Wilms tumor relapsing after initial treatment with vincristine and actinomycin D: A report from the National Wilms Tumor Study Group",
abstract = "Purpose. NWTS-5 was a multi-institutional clinical trial for patients less than 16 years of age at diagnosis with specific renal neoplasms who were diagnosed between August 1, 1995 and May 31, 2002. A uniform approach to the treatment of patients with relapse was employed. Patients and Methods. Seventy-two patients who relapsed after immediate nephrectomy (stages I and II), initial chemotherapy with vincristine (VCR) and actinomycin D and no radiation therapy were registered on stratum B of the NWTS-5 relapse protocol. Four patients were not evaluable: one due to insufficient data and three due to major protocol violations. Among the 68 remaining patients, one who was 19 years of age at initial diagnosis of Wilms tumor, five with bilateral Wilms tumor at diagnosis, three who developed a contralateral relapse, and one with persistent disease were not included in this analysis. Relapse treatment included surgical excision, when feasible, radiation therapy and alternating courses of VCR, doxorubicin and cyclophosphamide and etoposide and cyclophosphamide. Results. The outcomes of 58 patients were analyzed. The lung was the only site of relapse for 31 patients. Event-free survival 4 years after relapse was 71.1{\%} and 4-year overall survival was 81.8{\%} for all patients and were 67.8 and 81.0{\%} for those who relapsed only to their lungs. The most frequent toxicities were hematological. Conclusions. These results demonstrate that a significant proportion of children with Wilms tumor who relapse after initial treatment with VCR and actinomycin D can be successfully re-treated.",
keywords = "Chemotherapy, Pediatric oncology, Phase II clinical trials, Wilms tumor",
author = "Green, {Daniel M.} and Cotton, {Cecilia A.} and Marcio Malogolowkin and Breslow, {Norman E.} and Elizabeth Perlman and James Miser and Ritchey, {Michael L.} and Thomas, {Patrick R M} and Grundy, {Paul E.} and D'Angio, {Giulio J.} and Beckwith, {J. Bruce} and Shamberger, {Robert C.} and Haase, {Gerald M.} and Milton Donaldson and Robert Weetman and Coppes, {Max J.} and Patricia Shearer and Peter Coccia and Morris Kletzel and Roger Macklis and Gail Tomlinson and Vicki Huff and Robert Newbury and Douglas Weeks",
year = "2007",
month = "5",
day = "1",
doi = "10.1002/pbc.20822",
language = "English (US)",
volume = "48",
pages = "493--499",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Treatment of Wilms tumor relapsing after initial treatment with vincristine and actinomycin D

T2 - A report from the National Wilms Tumor Study Group

AU - Green, Daniel M.

AU - Cotton, Cecilia A.

AU - Malogolowkin, Marcio

AU - Breslow, Norman E.

AU - Perlman, Elizabeth

AU - Miser, James

AU - Ritchey, Michael L.

AU - Thomas, Patrick R M

AU - Grundy, Paul E.

AU - D'Angio, Giulio J.

AU - Beckwith, J. Bruce

AU - Shamberger, Robert C.

AU - Haase, Gerald M.

AU - Donaldson, Milton

AU - Weetman, Robert

AU - Coppes, Max J.

AU - Shearer, Patricia

AU - Coccia, Peter

AU - Kletzel, Morris

AU - Macklis, Roger

AU - Tomlinson, Gail

AU - Huff, Vicki

AU - Newbury, Robert

AU - Weeks, Douglas

PY - 2007/5/1

Y1 - 2007/5/1

N2 - Purpose. NWTS-5 was a multi-institutional clinical trial for patients less than 16 years of age at diagnosis with specific renal neoplasms who were diagnosed between August 1, 1995 and May 31, 2002. A uniform approach to the treatment of patients with relapse was employed. Patients and Methods. Seventy-two patients who relapsed after immediate nephrectomy (stages I and II), initial chemotherapy with vincristine (VCR) and actinomycin D and no radiation therapy were registered on stratum B of the NWTS-5 relapse protocol. Four patients were not evaluable: one due to insufficient data and three due to major protocol violations. Among the 68 remaining patients, one who was 19 years of age at initial diagnosis of Wilms tumor, five with bilateral Wilms tumor at diagnosis, three who developed a contralateral relapse, and one with persistent disease were not included in this analysis. Relapse treatment included surgical excision, when feasible, radiation therapy and alternating courses of VCR, doxorubicin and cyclophosphamide and etoposide and cyclophosphamide. Results. The outcomes of 58 patients were analyzed. The lung was the only site of relapse for 31 patients. Event-free survival 4 years after relapse was 71.1% and 4-year overall survival was 81.8% for all patients and were 67.8 and 81.0% for those who relapsed only to their lungs. The most frequent toxicities were hematological. Conclusions. These results demonstrate that a significant proportion of children with Wilms tumor who relapse after initial treatment with VCR and actinomycin D can be successfully re-treated.

AB - Purpose. NWTS-5 was a multi-institutional clinical trial for patients less than 16 years of age at diagnosis with specific renal neoplasms who were diagnosed between August 1, 1995 and May 31, 2002. A uniform approach to the treatment of patients with relapse was employed. Patients and Methods. Seventy-two patients who relapsed after immediate nephrectomy (stages I and II), initial chemotherapy with vincristine (VCR) and actinomycin D and no radiation therapy were registered on stratum B of the NWTS-5 relapse protocol. Four patients were not evaluable: one due to insufficient data and three due to major protocol violations. Among the 68 remaining patients, one who was 19 years of age at initial diagnosis of Wilms tumor, five with bilateral Wilms tumor at diagnosis, three who developed a contralateral relapse, and one with persistent disease were not included in this analysis. Relapse treatment included surgical excision, when feasible, radiation therapy and alternating courses of VCR, doxorubicin and cyclophosphamide and etoposide and cyclophosphamide. Results. The outcomes of 58 patients were analyzed. The lung was the only site of relapse for 31 patients. Event-free survival 4 years after relapse was 71.1% and 4-year overall survival was 81.8% for all patients and were 67.8 and 81.0% for those who relapsed only to their lungs. The most frequent toxicities were hematological. Conclusions. These results demonstrate that a significant proportion of children with Wilms tumor who relapse after initial treatment with VCR and actinomycin D can be successfully re-treated.

KW - Chemotherapy

KW - Pediatric oncology

KW - Phase II clinical trials

KW - Wilms tumor

UR - http://www.scopus.com/inward/record.url?scp=33947709022&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947709022&partnerID=8YFLogxK

U2 - 10.1002/pbc.20822

DO - 10.1002/pbc.20822

M3 - Article

VL - 48

SP - 493

EP - 499

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 5

ER -